View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
December 4, 2013

OncoMed and Celgene to develop new multiple anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals and Celgene have agreed to jointly develop and commercialise up to six therapies targeting cancer stem cells (CSCs) product candidates from OncoMed's biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).

By admin-demo

OncoMed Pharmaceuticals and Celgene have agreed to jointly develop and commercialise up to six therapies targeting cancer stem cells (CSCs) product candidates from OncoMed’s biologics pipeline, including demcizumab (OMP-21M18, Anti-DLL4).

As part of the development, OncoMed will manage and carry out initial clinical studies, while Celgene will have an option to license worldwide rights to up to six novel anti-CSC therapeutic candidates.

In addition, OncoMed retains global co-development and US co-commercialisation rights for five out of the six anti-CSC product candidates with equal US profit sharing, as well as royalties to be received in other territories.

The deal will also see Celgene have research, development and commercialisation rights to small molecule compounds in an undisclosed cancer stem cell pathway.

"The deal will also see Celgene have research, development and commercialisation rights to small molecule compounds in an undisclosed cancer stem cell pathway."

Celgene also gets an exclusive option on OncoMed’s demcizumab, during or after the completion of certain future planned Phase II clinical trials to be carried out by OncoMed.

Currently, demcizumab is in three Phase Ib clinical trials in combination with standard-of-care therapeutics, including a trial in patients with first-line advanced pancreatic cancer.

Subsequent to option exercise, both the firms will co-develop demcizumab, sharing global development costs on a 1/3 OncoMed and 2/3 Celgene basis, as well as co-commercialise the product in the US with 50/50 profit sharing.

Outside the US, Celgene will be responsible for the development and commercialisation, while OncoMed is eligible to receive milestones and tiered double-digit royalties on sales.

As well as demcizumab, the deal also includes up to five preclinical or discovery-stage biologics programmes such as OncoMed’s anti-DLL4/VEGF bispecific antibody and up to four additional biologics programmes targeting either the RSPO-LGR CSC pathway or an additional undisclosed CSC pathway.

On these programmes, Celgene will have exclusive options during or after completion of certain Phase I clinical trials to be carried out by OncoMed.

Under the deal, OncoMed will receive an upfront payment of $155m, and Celgene will also purchase about $22.25m in a private placement of newly issued shares of OncoMed’s common stock at a price of $15.13 for each share.

The deal also includes option exercise payments and payments for achievement of development, regulatory and commercial milestones, paid on an individual programme basis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology